Literature DB >> 3288054

Calcium antagonists as antiatherogenic agents.

P D Henry1.   

Abstract

Pharmacological manipulations of calcium metabolism in animals fed high-fat diets may slow the progression of atherosclerosis. Agents with calcium-chelating (diphosphonic acid and thiophene carboxylic acid derivatives) or calcium-channel-blocking properties (dihydropyridine derivatives, verapamil and its derivatives, diltiazem) have been demonstrated to suppress atherogenesis in rabbits and monkeys. The antiatherosclerotic effects appear to occur in the absence of hypolipidemic effects. The mechanisms of action of the structurally unrelated drugs remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288054     DOI: 10.1111/j.1749-6632.1988.tb33382.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

3.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 4.  Pathogenesis of atherosclerosis: state of the art.

Authors:  C C Haudenschild
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  An antioxidant role for calcium antagonists in the prevention of adrenaline mediated myocardial and endothelial damage.

Authors:  A A Noronha-Dutra; E M Steen-Dutra; N Woolf
Journal:  Br Heart J       Date:  1991-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.